A Review of Efficacy and Safety of Tenofovir and/or Emtricitabine for HIV Pre-exposure Prophylaxis based on Clinical Trials

다국어 초록 (Multilingual Abstract)

Oral tenofovir disoproxil fumarate (TDF) with or without emtricitabine (FTC) for preexposure prophylaxis (PrEP) against HIV infection in HIV-negative individuals can decrease the opportunities of HIV transmission. The current review aimed to assess efficacy and safety of TDF and FTC for PrEP against HIV infection and to provide clinical per-spectives on TDF and FTC for PrEP. A literature search of clinical studies published in PubMed and posted on Clin-icalTrials.gov website was carried out to identify studies assessing the efficacy and safety of TDF and FTC for HIV PrEP. Seventeen studies were examined in this review. TDF and TDF/FTC for HIV PrEP generally showed effectiveness com-pared with placebo. Irrespective of the primary HIV transmission routes, PrEP was highly effective when used; however, PrEP for vaginal exposure was not significantly protective against HIV transmission. The safety profile of PrEP was com-parable with that of placebo, but adverse events related with renal function and bone mineral density (BMD) seemed to take place more frequently among those who received PrEP compared with placebo. The data presented in this review suggest that PrEP in HIV-uninfected individuals could be effective for the prevention of HIV acquisition. PrEP could have negative effects on renal function and BMD.

목차 (Table of Contents)

• Experimental Methods
• Results
• Discussion
• Conclusion